No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial.
BACKGROUND Pentoxifylline ( PTF ) is a potential therapeutic agent in chronic kidney disease due to its antiinflammatory and antiproteinuric effects that may influence the progression of renal disease . SUBJECTS AND METHODS We conducted a prospect i ve r and omized trial of 91 patients with estimated glomerular filtration rate ( eGFR ) < 60 ml/min , calculated with 4-variable Modification of Diet in Renal Disease ( MDRD-4 ) Study equation . Patients were r and omly assigned to treatment with PTF 400 mg ( twice a day ) ( n=46 ) or to continue their usual therapy ( n=45 ) . Clinical , biochemical and inflammatory parameters were measured at baseline , and at 6 and 12 months of treatment . The objective of the study was to analyze the effect of PTF treatment on inflammatory markers and secondarily the effect on renal disease progression . RESULTS Baseline characteristics were similar in the 2 groups .  High-sensitivity C-reactive protein ( hs-CRP ) , serum fibrinogen and TNF-alpha decreased significantly in patients treated with PTF in comparison with the control group at 12 months ( p=0.002 , p=0.001 and p=0.000 , respectively ) . Median urinary albumin excretion did not decrease with PTF treatment . In the PTF group , there was no significant change in eGFR after 12 months ( from 42.3 ± 10.2 to 44.7 ± 11.3 ml/min per 1.73 m(2 ) ) , whereas in the control group there was a worsening by the end of the study ( from 40.1 ± 12.4 to 35.7 ± 13.4 ml/min per 1.73 m(2 ) ) ( p=0.000 between groups ) . CONCLUSIONS PTF treatment decreases inflammatory markers in chronic kidney disease and stabilizes renal function
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .